Sentences with phrase «cancer tests such»

I think in 10 years, we'll have cancer tests such that you take them once or twice a year, find out you have early - stage cancer, take care of it early, and move on.

Not exact matches

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

On the other hand, such tests do catch cancer and sometimes save lives.

Undergoing treatment now: Nursing is safe during diagnostic tests for cancer such as a mammogram (although it may be harder to read during lactation), X-ray, CAT scan, MRI, ultrasound, and biopsy.

Discuss with your doctor when to begin breast cancer screening exams and tests, such as clinical breast exams and mammograms.

Scientists say that these «gastric organoids» could also be used to understand diseases such as cancer, and to test the stomach's response to drugs.

The study has been tested in metastatic patients with different primary tumours such as breast, colon and lung cancer.

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

With this technology, scientists could design and rapidly test new peptides to treat cancer and other diseases, as well as more effective variants of existing peptides, such as insulin, Pentelute says.

One is that the cancer - related proteins used by the test reflect tissue damage and can also appear in people with inflammatory diseases such as arthritis.

A team led by Lu You, an oncologist at Sichuan University's West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month.

In lab tests, they show that one such particle can be produced in plants and it ferries small molecules to cancer cells.

Such tests, however, have mysteriously failed to flag mutations in 20 % to 30 % of European women with a family history of breast cancer, even when their cancer could be linked to BRCA1 by damage to chromosome 17, BRCA1's home.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

The system is being tested for further medical uses, such as detecting prostate cancer.

The researchers tested their technique by applying the light for 1 minute to human cervical cancer cells surrounded with common anti-cancer drugs such as epigallocatechin gallate (EGCG).

Using statistical tests, Kamangar combined the results from studies in the U.S., Europe, Iran, China and Japan to evaluate if H. pylori helps prevent either form of esophageal cancer in such a large and geographically diverse sample pool.

Medical devices range from the simple, such as Band - Aids, to the high - tech, such as imaging machines and the BRCA1 and BRCA2 molecular diagnostic tests for breast cancer (see sidebar).

«It's very surprising that the nematodes exhibited such a strong binary response to «cancer» versus «no cancer» urine,» says Michael Phillips at Menssana Research, a New Jersey - based company developing diagnostic tests based on people's breath.

HDAC inhibitors have been approved for use in blood cancers and are being tested for benefit in other cancers, such as breast, colorectal, gastric, liver, lung and prostate cancers that overexpress specific HDAC proteins.

In emergencies — a heart attack, an acute cancer, or an asthma attack — such tests will be valuable only if they rapidly deliver results.

Such a test «would be wrong, unethical, and an abuse of the research», said Dean Hamer, a senior researcher at the US National Cancer Institute in Bethesda, Maryland.

Medical researchers are talking about starting an online archive where they could post unreviewed results from clinical trials, such as one that tested this light therapy for cancer patients.

In contrast, higher payments for cancer screening tests (such as colonoscopy, mammography, and Pap tests) were not always linked with increased screenings among Medicaid beneficiaries.

The commission concludes that the tumours likely to result from the tests — such as thyroid or brain cancer — either can not be identified by screening or can not be treated.

Such an inexpensive and simple test could help transform the landscape of pancreatic cancer and help prevent many of the estimated 330,000 deaths that it causes worldwide each year.

Such cell - tracing techniques are the right approach to test the cancer stem cell model, says Sean Morrison, who studies stem cells and cancer at UTSMC and who was not involved in any of the studies.

As we raise more funds, we hope to support more testing — including a closer look at the role that particular sugars and macronutrients have on other disorders, such as diabetes, cancer and neurological conditions.

Seeing this microbe singlehandedly shift such a wide range of immune parameters calls for caution in interpreting personal DNA tests that claim to predict one's risk of a host of diseases from Alzheimer's to cancer.

These additional genetic elements, however, are already in use for screening and testing for diseases such as breast cancer, prostate cancer and autoimmune diseases, Richard Myers, president of HudsonAlpha Institute for Biotechnology in Ala., noted in the briefing.

Right now, the tests, which are available from several companies, mostly aid in treatment decisions for people already diagnosed with a particular form of cancer, such as prostate or lung.

In terms of diagnostics, it has six tests on the market, based on research in Iceland, that aim to measure risk of diseases such as heart attack and prostate cancer.

Mutations in known breast cancer genes such as BRCA1 and BRCA2 are identified in only approximately 20 per cent of women who are offered genetic testing for familial breast cancer.

At the Jackson Laboratory in Maine, gerontologist David Harrison and his team chose to test rapamycin, which is already approved for use in procedures such as kidney transplants, because previous research showed that the drug increases the life span of flies and may reduce cancer in mammals.

«It is uncommon for a genetic screen for a cancer to turn up such a strong candidate mutation, and for the mutation to be present in every single patient tested.»

In each year thousands of men had the test without having a discussion of how it could either benefit them, for instance via early detection of cancer, or lead to unnecessary adversity, such as a side effects from biopsy or unneeded treatment.

«Our next step is to see how long we can extend the cycling pattern, and test some of the STAT3 inhibitors currently in clinical trials for other indications such as cancer, as this could accelerate testing in humans,» added Sacco.

Without thorough assessments, such as blood tests or cancer screenings, such a diagnosis would be premature and would likely be wrong.

Rich and colleagues are now testing in mice whether combining Zika with traditional cancer treatments such as chemotherapy is more effective than either treatment by itself.

Richards describes how the adoption of some of the standard cancer therapies, such as 5 - Fluorouracil and Interferon, was not based on their passing the validity test Moertel and his colleagues had insisted upon in the case of vitamin C.

The research team is also developing and testing the system for use by people with other types of cancer and long - term conditions such as heart failure.

When such a biomarker test is perfected, it could be used not only to distinguish pancreatic cancer from chronic pancreatitis, but, potentially, as a screening test for patients at high risk for pancreatic cancer, Dr. Raimondo says.

To help detect genetic mutations and better understand this disease, a group of researchers at USU and the nationwide Cancer Genome Atlas Research Network examined 173 tumors, performing six genomic tests, such as DNA and RNA sequencing.

Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

Those firms often fear the risk and financial burden that comes with testing new and potentially dangerous compounds in children with cancer, but the scientific rationale for moving ahead with such trials «has never been greater,» says one pediatric cancer researcher.

Now, as a result of 10 years work, Huang and her team have created a cervical cancer screening technique that, based on an analysis of a very large dataset, has the potential to perform as well or better than human interpretation on other traditional screening results, such as Pap tests and HPV tests — at a much lower cost.

I have been especially interested in testing drugs that can inhibit MMPs in cancer models and in understanding why such drugs have not been effective in human cancer patients.

Because you have her whole genome, and not just a test for a single gene, you can potentially look for a vast number of other gene variants that raise the risk of other diseases of adulthood, such as the BRCA1 gene for breast cancer.

So, this drug also has been tested in cancer trials and also in some of the neurodegenerative diseases, such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

The researchers looked at several factors that might explain this racial difference, such as whether there were differences in tumor characteristics between black patients and white patients, or differences in a family history of breast cancer — both factors that a doctor must consider before deciding whether a genetic test will likely benefit a particular patient.